XENE Xenon Pharmaceuticals Inc.

2.90
+0.00  (0%)
Previous Close 2.90
Open 2.95
Price To book 1.04
Market Cap 52195418
Shares 17,998,420
Volume 51,904
Short Ratio 7.16
Av. Daily Volume 44,646

SEC filingsSee all SEC filings

  1. CT ORDER - Confidential treatment order 171089519
  2. CT ORDER - Confidential treatment order 171067752
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171005753
  4. 8-K - Current report 171005440
  5. 8-K - Current report 17931211

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to commence 1Q 2018.
GDC-0310
Phase 2 data released March 24, 2017 - endpoints not met.
XEN801
Acne
Phase 2b data released June 27, 2017. Endpoints not met.
TV-45070
Postherpetic neuralgia
Phase 2b trial did not meet endpoints - July 2015
TV-45070
Osteoarthritis

Latest News

  1. Xenon Pharmaceuticals, Inc. :XENE-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
  2. Xenon Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update
  3. Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2017 Financial Results and Provide Corporate Update
  4. Teva/Xenon Nerve Pain Candidate Fails in Phase II Study
  5. UPDATED: Xenon and Teva say mid-stage nerve pain drug missed primary, secondary endpoints
  6. Xenon Pharmaceuticals to Host Conference Call and Webcast Today at 9:00 a.m. Eastern Time to Discuss Topline Results from TV-45070 Phase 2b Clinical Trial in PHN
  7. Teva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with Post-Herpetic Neuralgia (PHN) Did Not Meet Primary Endpoint
  8. Xenon Pharmaceuticals, Inc. :XENE-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
  9. Edited Transcript of XENE earnings conference call or presentation 9-May-17 8:30pm GMT
  10. Xenon Pharmaceuticals reports 1Q loss
  11. Investor Network: Xenon Pharmaceuticals Inc. to Host Earnings Call
  12. Nuventra founder inks deal for new venture that could be worth as much as $49 million
  13. 3 of the Best & Worst Performing Drug Stocks of Q1
  14. Xenon Pharmaceuticals Falls as Acne Drug Fails Study, Pulse Biosciences Submits 510(k) to FDA
  15. Xenon Pharma Dumps Acne Drug After Study Failure

SEC Filings

  1. CT ORDER - Confidential treatment order 171089519
  2. CT ORDER - Confidential treatment order 171067752
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171005753
  4. 8-K - Current report 171005440
  5. 8-K - Current report 17931211
  6. 8-K - Current report 17888361
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 17827217
  8. 8-K - Current report 17826812
  9. DEF 14A - Other definitive proxy statements 17789009
  10. 8-K - Current report 17784947